ÂÜÀòÂÒÂ×

Amir Tavakkol is an experienced professional who has held various roles in the pharmaceutical industry. Amir started their career as a Research Investigator at Roche in 1993 and later worked as a Senior Associate at Colgate Palmolive from 1995 to 2002. From 2002 to 2007, they served as a Clinical Director for Lamisil & Famvir & Tobramycin at Novartis. Tavakkol then joined Schering Plough Inc as a Senior Director & Head of Dermatology Global Clinical Research from 2007 to 2009. Amir contributed to Merck & Co, Inc as a Product Development Team Leader from 2009 to 2011, focusing on antifungals. Tavakkol also worked at Topica Pharmaceuticals as Senior VP & Head of Clinical Development & Operations from 2011 to 2014. From 2014 to 2017, they served as the Chief Development Officer at Viamet Pharmaceuticals, leading drug development efforts for antifungal drugs. Tavakkol then joined Castle Creek Pharmaceuticals, LLC as an Executive Vice President & Chief Development Officer in 2017, where they built and led a strong R&D and medical affairs organization. In 2019, they took on the role of Chief Scientific Officer at Timber Pharmaceuticals and Moberg Pharma AB.

Amir Tavakkol has a diverse education history, starting with an Internship in Infectious Diseases at Seacroft Hospital, Leeds University from 1979 to 1980. Amir then pursued a degree in Dip. Bact. in Infectious Diseases at The University of Manchester from 1980 to 1981. Following this, they obtained a Ph.D. in Medical Microbiology from The University of Manchester between 1981 and 1984. Amir continued their academic journey at The Ohio State University, where they completed a NIH Post Doc in Endocrinology from 1986 to 1989.